Advancing multiple myeloma therapy: A systematic analysis of corticosteroids and monoclonal antibodies as dual therapeutic agents

doi:10.5662/wjm.v16.i1.107864

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 1

This Article

Google Scholar

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (89)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-3)

Sum=31

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=46

Mar 20, 2026 (publication date) through Feb 13, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Methodology

ISSN

2222-0682

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Methodol. Mar 20, 2026; 16(1): 107864
Published online Mar 20, 2026. doi: 10.5662/wjm.v16.i1.107864

Advancing multiple myeloma therapy: A systematic analysis of corticosteroids and monoclonal antibodies as dual therapeutic agents

Farah Alam, Huma Siddiqui, Arpna Nihal, Madiha Andleeb, Amna Qamar Uz Zaman, Mehwish Imam Khushk, Fatima Hussain, Rahul Rai, Fasiha Bakhtawar Fatima, Danaish Kumar, Syed Ali Farhan Abbas Rizvi, Shafaq Jabeen, Inshal Jawed, Umair Qadir, Mohammad Ali Zakeri

Farah Alam, Inshal Jawed, Umair Qadir, Department of Medicine, Dow University of Health Sciences, Karachi 75350, Sindh, Pakistan

Huma Siddiqui, Department of Pathology, Aga Khan University Hospital, Karachi 75300, Sindh, Pakistan

Arpna Nihal, Department of Haematology, Sindh Blood Transfusion, Karachi 75300, Sindh, Pakistan

Madiha Andleeb, Department of Pathology, Indus Hospital and Health Network, Karachi 75300, Sindh, Pakistan

Amna Qamar Uz Zaman, Fatima Hussain, Department of Haematology, Dr Ziauddin University and Hospital, Karachi 75300, Sindh, Pakistan

Mehwish Imam Khushk, Rahul Rai, Department of Haematology, Liaquat University of Medical and Health Sciences, Hyderabad 76090, Sindh, Pakistan

Fasiha Bakhtawar Fatima, Department of Medicine, DOW Medical College, Karachi 74200, Sindh, Pakistan

Danaish Kumar, Shafaq Jabeen, Department of Medicine, Karachi Dental and Medical College, Karachi 75600, Sindh, Pakistan

Syed Ali Farhan Abbas Rizvi, Department of Medicine, Jinnah Medical and Dental College, Karachi 74800, Sindh, Pakistan

Mohammad Ali Zakeri, Department of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan 7718796755, Kermān, Iran

Author contributions: Alam F, Siddiqui H, Nihal A, Andleeb M, Zaman AQU, Khushk MI, Hussain F, Rai R, Fasiha, Kumar D, Ali F, Jabeen S, Jawed I, Qadir U, and Zakeri MA designed the research study; Alam F, Nihal A, Andleeb M, Zaman AQU, Hussain F, Rai R, Fasiha, Kumar D, Ali F, Jabeen S, Jawed I, and Qadir U performed the literature search and data extraction; Siddiqui H, Khushk MI, and Zakeri MA contributed to study selection and quality assessment; Alam F, Siddiqui H, Nihal A, Jawed I, and Zakeri MA analyzed the data and wrote the manuscript; Andleeb M, Zaman AQU, Khushk MI, Hussain F, Rai R, Fasiha, Kumar D, Ali F, Jabeen S, and Qadir U contributed to manuscript revision and editing. All authors have read and approved the final manuscript.

Conflict-of-interest statement: All authors declare no conflicts of interest or financial interests related to the content of this manuscript.

PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

Corresponding author: Inshal Jawed, Chief Physician, Senior Researcher, Department of Medicine, Dow University of Health Sciences, Baba-e-urdu Karachi, Karachi 75350, Sindh, Pakistan. inshaljwd@gmail.com

Received: April 2, 2025
Revised: May 22, 2025
Accepted: July 29, 2025
Published online: March 20, 2026
Processing time: 317 Days and 22.5 Hours

Core Tip

Core Tip: Corticosteroids and monoclonal antibodies (mAbs) deliver extensive therapeutic value to patients with multiple myeloma (MM) by providing survival improvements, particularly for people with relapsed or refractory disease. The essential medication dexamethasone, alongside other corticosteroids, has long proved beneficial in treatment regimens because it decreases tumor size and works better with other treatments. The development of daratumumab and other mAbs introduced specific tumor cell antigen targeting, producing significant study results for high-risk patients. Modern advancements in cancer therapy have produced promising results, although ongoing research aims to address corticosteroid-related long-term effects, prevent infusion responses in mAbs, and decrease their costly nature.